Loading ...
Sorry, an error occurred while loading the content.

ChronVac-C Reducing HCV Viral Load Up to 99%

Expand Messages
  • scarletpaolicchi
    Best Wishes, Scarlet http://www.healthyhepper.com ChronVac-C Reducing HCV Viral Load Up to 99% Clinical Data Presented at Annual Scientific Meeting of the
    Message 1 of 1 , Feb 12, 2009
      Best Wishes,

      ChronVac-C Reducing HCV Viral Load Up to 99%

      Clinical Data Presented at Annual Scientific Meeting of the American
      Association for the Study of Liver Diseases

      SAN DIEGO, Nov 17, 2008 (BUSINESS WIRE) -- Inovio Biomedical
      Corporation (INO 0.22, +0.04, +20.2%), a leader in enabling the
      development of DNA vaccines using electroporation-based DNA delivery,
      announced today that its partner, Tripep AB, reported positive
      additional interim results from its ongoing phase I/II clinical study
      of its therapeutic DNA vaccine against hepatitis C virus (HCV). This
      vaccine is being delivered using Inovio's electroporation-based DNA
      delivery system. In the third and highest dose cohort of the study,
      two of three subjects demonstrated reductions in viral load of 93% and
      99.7%. Previously reported middle dose cohort results demonstrated an
      87% and 98% reduction in HCV in two of three subjects, while no
      anti-viral effect was observed in the low dose cohort. No safety
      issues have been noted to date in the trial. These data suggest a
      potential dose response of the vaccine and support the inclusion of
      three additional subjects in the high dose cohort.

      These data were presented by Dr. Matti Sanllberg of Tripep at the
      recent American Association for the Study of Liver Diseases meeting
      held in San Francisco.

      Avtar Dhillon, MD, Inovio's president and CEO, stated: "We continue to
      be encouraged by the data flowing out of the ChronVac-C study. This
      promising DNA vaccine candidate, in which Inovio has an ownership
      position, is one of the more advanced clinical vaccine candidates in
      the HCV field. ChronVac-C was designed to play a role as a first-line
      therapy or as an adjunct to existing therapies."

      About ChronVac-C

      ChronVac-C(R) is a therapeutic DNA-based vaccine given to individuals
      already infected with the hepatitis C virus with the aim of clearing
      the infection from the liver by boosting the body's immune response
      against the virus. Inovio's electroporation technology is being used
      to deliver the vaccine and is intended to enhance the potency of the
      DNA vaccine. This clinical study is being conducted at the Infectious
      Disease Clinic and Center for Gastroenterology at the Karolinska
      University Hospital in Huddinge and Solna, respectively, in Sweden.
      The intended enrollment of 12 patients is being divided into four
      groups, three with increasing doses of ChronVac-C and the fourth at
      the maximum tolerable dose. Each patient receives four vaccinations
      one month apart. After the last vaccination, patients are followed for
      another six months. The study's main purpose is to assess safety. It
      is also testing whether the treatment boosts the immune response
      (immunogenicity) to HCV and its effect on virus replication in the liver.

      About Inovio Biomedical Corporation

      Inovio Biomedical is focused on developing DNA vaccines for cancers
      and infectious diseases using its novel method for DNA delivery --
      electroporation -- which uses brief, controlled electrical pulses to
      increase cellular uptake of useful biopharmaceuticals. Initial human
      data has shown that Inovio's electroporation-based DNA delivery
      technology can significantly increase gene expression and immune
      responses from DNA vaccines. Immunotherapy partners include Merck,
      Wyeth, Vical, University of Southampton, Moffitt Cancer Center, the
      U.S. Army, National Cancer Institute, and International Aids Vaccine
      Initiative. Inovio's technology is protected by an extensive patent
      portfolio covering in vivo electroporation. The company has entered
      into a definitive merger agreement with VGX Pharmaceuticals. More
      information is available at www.inovio.com.

      This press release contains certain forward-looking statements
      relating to our plans to develop our electroporation drug and gene
      delivery technology. Actual events or results may differ from our
      expectations as a result of a number of factors, including the
      uncertainties inherent in clinical trials and product development
      programs (including, but not limited to, the fact that pre-clinical
      and clinical results referenced in this release may not be indicative
      of results achievable in other trials or for other indications and
      that results from one study may not necessarily be reflected or
      supported by the results of other similar studies), the availability
      of funding to support continuing research and studies in an effort to
      prove safety and efficacy of Inovio's technology as a delivery
      mechanism, the availability or potential availability of alternative
      therapies or treatments for the conditions targeted by Inovio or its
      collaborators, including alternatives that may be more efficacious or
      cost-effective than any therapy or treatment that Inovio and its
      collaborators hope to develop, evaluation of potential opportunities,
      issues involving patents and whether they or licenses to them will
      provide Inovio with meaningful protection from others using the
      covered technologies, whether such proprietary rights are enforceable
      or defensible or infringe or allegedly infringe on rights of others or
      can withstand claims of invalidity and whether Inovio can finance or
      devote other significant resources that may be necessary to prosecute,
      protect or defend them, the level of corporate expenditures,
      assessments of our technology by potential corporate or other partners
      or collaborators, capital market conditions, and other factors set
      forth in our Annual Report on Form 10-K for the year ended December
      31, 2007, our 10-Q for the nine months ended September 30, 2008 and
      other regulatory filings from time to time. There can be no assurance
      that any product in our product pipeline will be successfully
      developed or manufactured, that final results of clinical studies will
      be supportive of regulatory approvals required to market licensed
      products, or that any of the forward-looking information provided
      herein will be proved accurate.

      SOURCE: Inovio Biomedical Corporation

      URL for Article Source:
    Your message has been successfully submitted and would be delivered to recipients shortly.